165 related articles for article (PubMed ID: 20678801)
1. Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application.
Shen L; You Y; Sun S; Chen Y; Qu J; Cheng L
Ophthalmology; 2010 Dec; 117(12):2365-71. PubMed ID: 20678801
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes.
Park HJ; Lee JE; Kim SI; Pak KY; Oum BS; Lee JS; Jung JH; Lee JE
Retina; 2014 Apr; 34(4):801-6. PubMed ID: 24077088
[TBL] [Abstract][Full Text] [Related]
3. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.
Beer PM; Bakri SJ; Singh RJ; Liu W; Peters GB; Miller M
Ophthalmology; 2003 Apr; 110(4):681-6. PubMed ID: 12689886
[TBL] [Abstract][Full Text] [Related]
4. Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection.
Cheng L; Banker AS; Martin M; Kozak I; Freeman WR
Ophthalmology; 2009 Jul; 116(7):1356-9. PubMed ID: 19450879
[TBL] [Abstract][Full Text] [Related]
5. Intraocular availability of triamcinolone acetonide after intravitreal injection.
Jonas JB
Am J Ophthalmol; 2004 Mar; 137(3):560-2. PubMed ID: 15013884
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon's injection.
Kovacs K; Wagley S; Quirk MT; Ceron OM; Silva PA; Singh RJ; Gukasyan HJ; Arroyo JG
Am J Ophthalmol; 2012 May; 153(5):939-48. PubMed ID: 22310078
[TBL] [Abstract][Full Text] [Related]
7. Transscleral permeation of subtenon triamcinolone in different vitreoretinal diseases.
Shen L; Mao J; Chen Y; Sun S; Han Y; Cheng L
Ophthalmology; 2015 Mar; 122(3):649-51. PubMed ID: 25439434
[No Abstract] [Full Text] [Related]
8. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.
Kamppeter BA; Cej A; Jonas JB
Ophthalmology; 2008 Aug; 115(8):1372-5. PubMed ID: 18355920
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone acetonide concentration after subtenon injection.
Thomas ER; Wang J; Ege E; Madsen R; Hainsworth DP
Am J Ophthalmol; 2006 Nov; 142(5):860-1. PubMed ID: 17056371
[TBL] [Abstract][Full Text] [Related]
10. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection.
Inoue M; Takeda K; Morita K; Yamada M; Tanigawara Y; Oguchi Y
Am J Ophthalmol; 2004 Dec; 138(6):1046-8. PubMed ID: 15629301
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection.
Nan K; Sun S; Li Y; Qu J; Li G; Luo L; Chen H; Cheng L
Br J Ophthalmol; 2010 May; 94(5):654-8. PubMed ID: 20447969
[TBL] [Abstract][Full Text] [Related]
12. Development of biodegradable controlled release scleral systems of triamcinolone acetonide.
Blatsios G; Tzimas AS; Mattheolabakis G; Panagi Z; Avgoustakis K; Gartaganis SP
Curr Eye Res; 2010 Oct; 35(10):916-24. PubMed ID: 20858113
[TBL] [Abstract][Full Text] [Related]
13. Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection.
Silva PS; Singh RJ; Bakri SJ; Lising RS; Santiago DE; Uy HS
Ocul Immunol Inflamm; 2009; 17(3):216-20. PubMed ID: 19585367
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of triamcinolone acetonide after intravitreal injection.
Degenring RF; Jonas JB
Am J Ophthalmol; 2004 Jun; 137(6):1142-3. PubMed ID: 15183810
[TBL] [Abstract][Full Text] [Related]
15. Systemic absorption of triamcinolone acetonide after posterior sub-Tenon injection.
Zaka-ur-Rab S; Mahmood S; Shukla M; Zakir SM; Khan BA; Owais M
Am J Ophthalmol; 2009 Sep; 148(3):414-9. PubMed ID: 19464668
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes.
Mason JO; Somaiya MD; Singh RJ
Retina; 2004 Dec; 24(6):900-4. PubMed ID: 15579987
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.
Chen M; Li X; Liu J; Han Y; Cheng L
J Control Release; 2015 Apr; 203():109-17. PubMed ID: 25700623
[TBL] [Abstract][Full Text] [Related]
19. Quantification of triamcinolone acetonide in ocular tissues after intravitreal injection to rabbit using liquid chromatography-tandem mass spectrometry.
Zhang SQ
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Mar; 879(7-8):548-52. PubMed ID: 21296037
[TBL] [Abstract][Full Text] [Related]
20. Subtenon Triamcinolone Acetonide Removal for Uncontrolled Ocular Hypertension After Posterior Subtenon Injection of Triamcinolone Acetonide.
Chan LW; Hsu WC; Hsieh YT
J Glaucoma; 2016 Mar; 25(3):e268-72. PubMed ID: 26950466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
